Key Points
- Insider sale: Mark Hopman sold 36,870 Beta Bionics shares for approximately $680,620 under a pre-arranged Rule 10b5-1 plan, reducing his ownership by 29.73% to 87,157 shares.
- Stock and financial performance: BBNX opened at $16.59, down 4.8%, while the company reported quarterly revenue of $32.01 million and an adjusted EPS loss of $0.53, beating analyst expectations.
- Analyst outlook and risks: Analysts maintain a “Moderate Buy” consensus with an average price target of $20.10, but the company faces securities-class-action allegations related to disclosures about its iLet insulin pump’s safety, quality, and regulatory status.
Beta Bionics, Inc. (NASDAQ:BBNX - Get Free Report) insider Mark Hopman sold 36,870 shares of the stock in a transaction that occurred on Wednesday, September 9th. The stock was sold at an average price of $18.46, for a total value of $680,620.20. Following the transaction, the insider owned 87,157 shares in the company, valued at $1,608,918.22. The trade was a 29.73% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Mark Hopman also recently made the following trade(s):
- On Wednesday, September 2nd, Mark Hopman sold 5,327 shares of Beta Bionics stock. The stock was sold at an average price of $19.11, for a total transaction of $101,798.97.
- On Wednesday, June 24th, Mark Hopman sold 1,258 shares of Beta Bionics stock. The shares were sold at an average price of $15.01, for a total transaction of $18,882.58.
Beta Bionics Stock Down 4.8%
Beta Bionics stock opened at $16.59 on Friday. Beta Bionics, Inc. has a 12-month low of $8.80 and a 12-month high of $32.71. The firm's fifty day moving average is $17.30 and its 200 day moving average is $13.78. The company has a market capitalization of $746.38 million, a PE ratio of -10.05 and a beta of 3.37.
Beta Bionics (NASDAQ:BBNX - Get Free Report) last issued its earnings results on Wednesday, July 29th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.62) by $0.09. The business had revenue of $32.01 million for the quarter. Beta Bionics had a negative net margin of 61.31% and a negative return on equity of 26.30%. Sell-side analysts expect that Beta Bionics, Inc. will post -2.1 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Several analysts have recently commented on BBNX shares. Bank of America reduced their target price on Beta Bionics from $23.00 to $11.00 and set a "neutral" rating for the company in a research note on Monday, May 18th. William Blair began coverage on Beta Bionics in a research note on Friday, August 21st. They set a "market perform" rating on the stock. Truist Financial increased their price target on Beta Bionics from $18.00 to $22.00 and gave the stock a "buy" rating in a report on Monday, July 13th. UBS Group initiated coverage on Beta Bionics in a research note on Tuesday, July 28th. They issued a "buy" rating and a $22.00 price objective for the company. Finally, Weiss Ratings upgraded Beta Bionics from a "sell (e+)" rating to a "sell (d-)" rating in a report on Tuesday, August 18th. Seven research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $20.10.
Get Our Latest Analysis on BBNX
Institutional Inflows and Outflows
Large investors have recently made changes to their positions in the business. BlackRock Inc. acquired a new stake in shares of Beta Bionics in the 2nd quarter worth about $52,340,000. Vanguard Group Inc. boosted its stake in Beta Bionics by 213.5% during the 3rd quarter. Vanguard Group Inc. now owns 2,216,185 shares of the company's stock valued at $44,036,000 after purchasing an additional 1,509,217 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in Beta Bionics during the 4th quarter valued at about $40,437,000. Eversept Partners LP increased its holdings in Beta Bionics by 108.6% during the 1st quarter. Eversept Partners LP now owns 1,414,838 shares of the company's stock worth $14,177,000 after purchasing an additional 736,576 shares in the last quarter. Finally, 12 West Capital Management LP bought a new stake in Beta Bionics during the 4th quarter worth approximately $17,520,000.
Key Beta Bionics News
Here are the key news stories impacting Beta Bionics this week:
- Negative Sentiment: Several firms reminded investors of the November 3, 2026 deadline to seek lead-plaintiff status in a securities class action covering investors who purchased BBNX shares from July 30, 2025, through February 24, 2026. Robbins LLP class action notice
- Negative Sentiment: The allegations contend that Beta Bionics and certain officers misled investors about the safety, efficacy, and regulatory status of its iLet insulin pump. The complaints reportedly focus on disclosures concerning an FDA Warning Letter, quality-system “non-conformities,” and allegedly unreported customer complaints involving potentially life-threatening hypoglycemia. SueWallSt shareholder alert
- Negative Sentiment: Insider Mark Hopman sold 36,870 shares for approximately $680,620, reducing his direct ownership by about 29.7%. The sale was executed under a pre-arranged Rule 10b5-1 plan, which reduces—but does not eliminate—the negative signaling effect. Beta Bionics insider transaction
- Neutral Sentiment: Reported short interest was zero as of September 10, unchanged from the prior period, with a zero-day short-interest ratio. This data point provides no evidence of meaningful short selling, although the zero figures may reflect incomplete or anomalous reporting.
About Beta Bionics
(
Get Free Report)
Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company's flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.
At the core of Beta Bionics' offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
